---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-22-000148"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2022-02-02T23:59:59+00:00"
generated_at: "2026-06-27T12:14:22.902765+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# Anavex Life Sciences releases data presentation via webcast; details not disclosed in filing

## Summary
- CEO Christopher Missling and CMO Ed Hammond presented data via webcast on February 2, 2022.
- Exhibit 99.1 referenced but not included in provided text; content unknown.
- No financial or clinical results specified in the 8-K filing.
- Investors should review the full presentation for material information.

## SEC filing metadata
- accession: 0001731122-22-000148
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2022-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112222000148/0001731122-22-000148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112222000148/e3468_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-22-000148
- JSON: https://secwatch.observer/filing/0001731122-22-000148.json
- Plain text: https://secwatch.observer/filing/0001731122-22-000148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.